Risk Factors
437 articles
Harnessing the Power of Radionuclide Therapy
Julie Sutcliffe is working with targeted radionuclide therapy to go after pancreatic cancer cells that have spread beyond the pancreas.
Using Tumor Tissue Samples to Break Down Assumptions About Pancreatic Cancer
Dr. Christine Iacobuzio-Donahue uses tumor tissue samples to study how pancreatic cancer tumors develop, so she can find ways to stop the disease.
For Pancreatic Cancer Patients, Pain Control Through Targeted Radiotherapy
Dr. Yaacov Lawrence is using celiac plexus radiotherapy in a clinical trials to target a source of pain for pancreatic cancer patients.
Study Shows Fungi Boost Pancreatic Cancer Development and Growth
Drs. George Miller and Berk Aykut are leading research into the role of fungi in the growth and development of pancreatic cancer.
Taking a Systems Biology Approach to Find a New Pancreatic Cancer Target
Dr. Andrea Califano is using systems biology and cell regulators to find new targets in the search for ways to stop pancreatic cancer cells.
Inhibiting Cell Division With Alternating Electric Fields
Dr. Andrew Coveler explains how electric fields are being used to disrupt pancreatic cancer cell division, to make tumors more removable.
Challenge Grant Recipients Moving Forward
The Pancreatic Cancer Collective awarded four teams a second round of New Therapies Challenge Grants, to further develop new pancreatic cancer treatment.
Tumor Biology Matters
Dr. Lynn Matrisian of PanCAN, explains that molecular profiling of a pancreatic cancer patient’s tumor can show which treatment will work best.
COMBATing Pancreatic Cancer
Dr. Manuel Hidalgo explains the COMBAT trial, which combines immunotherapy, a checkpoint inhibitor, and chemotherapy to attack pancreatic cancer.
NALIRIFOX Shows Promise in Early Studies
Dr. Zev Wainberg describes the new combination NALIRIFOX, being tested in the NAPOLI-3 clinical trial for advanced pancreatic cancer patients.
Shedding More Light On Neoadjuvant Treatment
Dr. Matthew Katz reviews the study that compared neoadjuvant treatment with FOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic cancer.
AACR Virtual Special Conference on Pancreatic Cancer: Day One Highlights
Let’s Win and the Lustgarten Foundation present highlights of Day One of the AACR Virtual Special Conference on Pancreatic Cancer.
An Interview with Dr. Tyler Jacks
Dr. Tyler Jacks is one of the leading pancreatic cancer researchers. Read what he has to say about KRAS, organoids, and running a lab in a pandemic.
Tumor Subtypes Potentially Provide Clues About Prognosis and Treatment
Drs. Andrew Aguirre and David Ting are teasing out the differences between pancreatic cancer subtypes, to get treatments that work better.
Multi-Site Precision Promise Study Opens
Dr. Vincent Picozzi explains how Precision Promise clinical trial will use a personalized approach for pancreatic cancer patients.